See more : iROC Co., Ltd. (3555.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Amed Co., Ltd. (7575.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amed Co., Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Nubian Resources Ltd. (NBRFF) Income Statement Analysis – Financial Results
- PureTech Health plc (PTCHF) Income Statement Analysis – Financial Results
- Speedvalue Ltd (SPDV.TA) Income Statement Analysis – Financial Results
- Xingye Wulian Service Group Co. Ltd. (9916.HK) Income Statement Analysis – Financial Results
- JG Summit Holdings, Inc. (JGSHF) Income Statement Analysis – Financial Results
Amed Co., Ltd. (7575.TWO)
About Amed Co., Ltd.
Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name. The company also provides 7-day long-acting pain reliever injections under the Naldebain brand name. In addition, it offers pressure injectable implantable port kits under the POLYSITE brand; and universal linear cutting staplers under the easyEndo brand name. The company was founded in 2008 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 763.82M | 689.65M | 559.11M | 475.06M | 0.00 |
| Cost of Revenue | 239.27M | 193.71M | 147.05M | 117.73M | 0.00 |
| Gross Profit | 524.56M | 495.94M | 412.06M | 357.33M | 0.00 |
| Gross Profit Ratio | 68.68% | 71.91% | 73.70% | 75.22% | 0.00% |
| Research & Development | 25.70M | 20.75M | 17.50M | 19.56M | 0.00 |
| General & Administrative | 83.79M | 83.68M | 60.11M | 53.51M | 0.00 |
| Selling & Marketing | 291.66M | 279.45M | 260.41M | 226.55M | 0.00 |
| SG&A | 375.45M | 363.13M | 320.52M | 280.06M | 0.00 |
| Other Expenses | 0.00 | 600.00K | 1.13M | 1.88M | 0.00 |
| Operating Expenses | 385.95M | 383.88M | 338.02M | 299.62M | 0.00 |
| Cost & Expenses | 640.54M | 577.59M | 485.06M | 417.36M | 0.00 |
| Interest Income | 598.00K | 145.00K | 31.00K | 27.00K | 39.00K |
| Interest Expense | 6.66M | 6.21M | 5.45M | 5.20M | 6.55M |
| Depreciation & Amortization | 28.43M | 33.40M | 30.98M | 28.39M | 0.00 |
| EBITDA | 157.33M | 144.96M | 106.21M | 87.43M | 69.34M |
| EBITDA Ratio | 20.60% | 21.45% | 19.03% | 18.43% | 0.00% |
| Operating Income | 123.29M | 114.54M | 75.45M | 59.16M | 0.00 |
| Operating Income Ratio | 16.14% | 16.61% | 13.49% | 12.45% | 0.00% |
| Total Other Income/Expenses | -1.05M | -6.70M | -5.66M | -5.32M | -1.66M |
| Income Before Tax | 122.23M | 105.36M | 69.78M | 53.84M | 0.00 |
| Income Before Tax Ratio | 16.00% | 15.28% | 12.48% | 11.33% | 0.00% |
| Income Tax Expense | 30.52M | 28.11M | 20.04M | 17.73M | 0.00 |
| Net Income | 91.72M | 77.25M | 49.74M | 36.11M | 0.00 |
| Net Income Ratio | 12.01% | 11.20% | 8.90% | 7.60% | 0.00% |
| EPS | 3.06 | 2.58 | 1.66 | 1.21 | 0.78 |
| EPS Diluted | 3.05 | 2.57 | 1.64 | 1.20 | 0.78 |
| Weighted Avg Shares Out | 30.00M | 30.00M | 30.00M | 30.00M | 29.16M |
| Weighted Avg Shares Out (Dil) | 30.08M | 30.07M | 30.35M | 30.00M | 29.16M |
Source: https://incomestatements.info
Category: Stock Reports